Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study
Brain · 04.04.2024 · 147 (4) · 1377-1388
DOI: 10.1093/brain/awad338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 03.10.2023. Verfasst von Chloé Laurencin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Lyon Neuroscience Research Center (CRNL), INSERM U1028, CNRS UMR5292, University Lyon 1, F-69000 Lyon, France. Hauptthemen laut MEDLINE: Parkinson Disease, Melanins. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: French National Agency of Research, France Parkinson.
Abstract (Originalsprache)
Degeneration of the noradrenergic system is now considered a pathological hallmark of Parkinson’s disease, but little is known about its consequences in terms of parkinsonian manifestations. Here, we evaluated two aspects of the noradrenergic system using multimodal in vivo imaging in patients with Parkinson’s disease and healthy controls: the pigmented cell bodies of the locus coeruleus with neuromelanin sensitive MRI; and the density of α2-adrenergic receptors (ARs) with PET using 11C-yohimbine. Thirty patients with Parkinson’s disease and 30 age- and sex-matched healthy control subjects were included. The characteristics of the patients’ symptoms were assessed using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). Patients showed reduced neuromelanin signal intensity in the locus coeruleus compared with controls and diminished 11C-yohimbine binding in widespread cortical regions, including the motor cortex, as well as in the insula, thalamus and putamen. Clinically, locus coeruleus neuronal loss was correlated with motor (bradykinesia, motor fluctuations, tremor) and non-motor (fatigue, apathy, constipation) symptoms. A reduction of α2-AR availability in the thalamus was associated with tremor, while a reduction in the putamen, the insula and the superior temporal gyrus was associated with anxiety. These results highlight a multifaceted alteration of the noradrenergic system in Parkinson’s disease since locus coeruleus and α2-AR degeneration were found to be partly uncoupled. These findings raise important issues about noradrenergic dysfunction that may encourage the search for new drugs targeting this system, including α2-ARs, for the treatment of Parkinson’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lyon Neuroscience Research Center (CRNL), INSERM U1028, CNRS UMR5292, University Lyon 1, F-69000 Lyon, France.
- Department of Neurology C, Expert Parkinson Centre, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, NS-Park/F-CRIN, 69500 Bron, France.
- CERMEP-Imagerie du Vivant, PET-MRI Department, 69500 Bron, France.
- Institut des Sciences Cognitives Marc Jeannerod, UMR 5229, CNRS, 69500 Bron, France.
ORCID-Profile: Bénédicte Ballanger
Förderung
- French National Agency of Research
- France Parkinson
Zitieren
APA
Laurencin, C., Lancelot, S., Brosse, S., Mérida, I., Redouté, J., Greusard, E., Lamberet, L., Liotier, V., Le Bars, D., Costes, N., Thobois, S., Boulinguez, P., & Ballanger, B. (2024). Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study. Brain, 147(4), 1377-1388. https://doi.org/10.1093/brain/awad338
Vancouver
Laurencin C, Lancelot S, Brosse S, Mérida I, Redouté J, Greusard E, et al. Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study. Brain. 2024;147(4):1377-1388. doi:10.1093/brain/awad338
BibTeX
@article{Laurencin2024,
author = {Laurencin, Chloé and Lancelot, Sophie and Brosse, Sarah and Mérida, Inés and Redouté, Jérôme and Greusard, Elise and Lamberet, Ludovic and Liotier, Véronique and Le Bars, Didier and Costes, Nicolas and Thobois, Stéphane and Boulinguez, Philippe and Ballanger, Bénédicte},
title = {Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study},
journal = {Brain},
year = {2024},
volume = {147},
number = {4},
pages = {1377--1388},
doi = {10.1093/brain/awad338}
}
EUVIMED